celecoxib has been researched along with Sjogren's Syndrome in 3 studies
Sjogren's Syndrome: Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The psoriatic arthritis was treated with celecoxib and multiple sclerosis with fingolimod." | 5.38 | A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart? ( Cocco, G, 2012) |
| "The psoriatic arthritis was treated with celecoxib and multiple sclerosis with fingolimod." | 1.38 | A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart? ( Cocco, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cocco, G | 1 |
| Rosenstein, ED | 1 |
| Kushner, LJ | 1 |
| Kramer, N | 1 |
| Hachulla, E | 1 |
3 other studies available for celecoxib and Sjogren's Syndrome
| Article | Year |
|---|---|
A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?
Topics: Arthritis, Psoriatic; Atrial Fibrillation; Autoimmune Diseases; Celecoxib; Cyclooxygenase Inhibitors | 2012 |
Rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aurothioglucos | 1999 |
[64th Congress of the American College of Rheumatology, Philadelphia, October 28-November 2, 2000].
Topics: Amyloidosis; Antiphospholipid Syndrome; Behcet Syndrome; Celecoxib; Cyclooxygenase Inhibitors; Giant | 2001 |